REG1A and Its Receptor EXTL3 Are Prognostic Markers for Colorectal Cancer Recurrence
September 13, 2006
Field(s) of Research
: Cellular and Molecular Biology, Experimental and Molecular Therapeutics, Tumor Biology
CHICAGO -- Two genes, known as REG1A and EXTL3, are overexpressed in colorectal tumors of patients who are at high risk of recurrence, according to a new study from the Max Delbrueck Center in Berlin, Germany.
In this study, REG1A expression was also significantly higher in surgical biopsies taken from pre-cancerous colon polyps, or adenomas.
“The findings suggest that the two genes are significant prognostic markers and may eventually help in making decisions about management of colorectal adenomas and tumors,” said principal investigator Wolfgang Kemmner, Ph.D., who is Surgical Oncology Research Group Leader at the Max Delbrueck Center.
Results were presented at the first meeting on Molecular Diagnostics in Cancer Therapeutic Development, organized by the American Association for Cancer Research.
The researchers analyzed tumor and normal tissue from 75 colorectal cancer patients who had undergone surgery but not yet received any other treatment. They discovered that REG1A (Regenerating Islet-Derived 1 Alpha) was overexpressed in tumor specimens compared to normal tissue. In general, its level of expression correlated with the length of time before the disease recurred--as REG1A expression levels increased, disease-free survival decreased.
Patients with higher expression levels also tended to have lower disease-specific survival, meaning less time before they died from their disease. In addition, REG1A expression was significantly higher in tumors with peritoneal carcinomatosis, a type of advanced cancer in which many small tumors develop on the abdominal cavity and linings.
The other gene, EXTL3 (Exostoses (Multiple)-Like 3), which was examined in samples of 56 patients, also tended to be upregulated in peritoneal carcinomatosis and was a significant predictor of patient outcome. EXTL3 encodes the receptor to which the REG1A protein binds.
Turning to precancerous adenomas, the researchers compared adenoma tissue from 22 patients to colorectal mucosal tissue from 31 healthy individuals. REG1A expression was significantly higher in the adenomas.
Taken together, the findings raise the possibility that the genes could help guide decisions regarding both treatment and prevention of the disease.
“On the one hand, determining REG1A and EXTL3 expression levels could eventually help show which surgical patients are at high risk for recurrence and thus need more aggressive treatment,” Kemmner said. “In addition, REG1A expression may serve in molecular diagnosis of very early tumors not yet apparent from conventional histopathology.”
# # # #
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 24,000 basic, translational, and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 60 other countries. AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment, and patient care. AACR publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. Its most recent publication, CR, is a magazine for cancer survivors, patient advocates, their families, physicians, and scientists. It provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship, and advocacy.
Warren R. Froelich
215/440-9300, ext. 198
In Chicago 9/12-9/15/06: